Dean Schorno Biography and Net Worth

Dean Schorno was appointed as Executive Vice President and Chief Financial Officer (CFO) in May 2018. Mr. Schorno joined Rigel from 23andMe, Inc., the leading consumer genetics and research company, where he had been CFO since 2015. Before joining 23andMe, Mr. Schorno was CFO of Adaptive Biotechnologies (Seattle, WA) and Genomic Health (Redwood City, CA). During this time, he led financial operations through periods of significant business and commercial growth which included significant financing and commercial transaction activity. Mr. Schorno began his career in finance at an international accounting firm in San Francisco, CA before starting his own consultancy in 1991. A certified public accountant, Mr. Schorno is a graduate of the University of California, Berkeley (BS, Business Administration) and Golden Gate University (MS, Taxation).

What is Dean L. Schorno's net worth?: The estimated net worth of Dean L. Schorno is at least $2.79 million as of February 4th, 2025. Schorno owns 58,969 shares of Rigel Pharmaceuticals stock worth more than $2,793,951 as of December 5th. This net worth approximation does not reflect any other assets that Schorno may own. Additionally, Schorno receives an annual salary of $736,720.00 as CFO at Rigel Pharmaceuticals. Learn More about Dean L. Schorno's net worth.
How old is Dean L. Schorno?: Schorno is currently 61 years old. There are 5 older executives and no younger executives at Rigel Pharmaceuticals. The oldest executive at Rigel Pharmaceuticals is Mr. Raul R. Rodriguez, President, CEO & Director, who is 63 years old. Learn More on Dean L. Schorno's age.
What is Dean L. Schorno's salary?: As the CFO of Rigel Pharmaceuticals, Inc., Schorno earns $736,720.00 per year. There are 2 executives that earn more than Schorno. The highest earning executive at Rigel Pharmaceuticals is Mr. Raul R. Rodriguez, President, CEO & Director, who commands a salary of $1,170,000.00 per year. Learn More on Dean L. Schorno's salary.
How do I contact Dean L. Schorno?: The corporate mailing address for Schorno and other Rigel Pharmaceuticals executives is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. Rigel Pharmaceuticals can also be reached via phone at (650) 624-1100 and via email at [email protected]. Learn More on Dean L. Schorno's contact information.
Has Dean L. Schorno been buying or selling shares of Rigel Pharmaceuticals?: Dean L. Schorno has not been actively trading shares of Rigel Pharmaceuticals during the last ninety days. Most recently, Dean L. Schorno sold 2,036 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a transaction totalling $42,593.12. Following the completion of the sale, the chief financial officer now directly owns 58,969 shares of the company's stock, valued at $1,233,631.48. Learn More on Dean L. Schorno's trading history.
Who are Rigel Pharmaceuticals' active insiders?: Rigel Pharmaceuticals' insider roster includes Raul Rodriguez (CEO), David Santos (EVP), and Dean Schorno (CFO). Learn More on Rigel Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Rigel Pharmaceuticals?: In the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 9,113 shares worth more than $190,643.96. The most recent insider tranaction occured on February, 4th when CFO Dean L Schorno sold 2,036 shares worth more than $42,593.12. Insiders at Rigel Pharmaceuticals own 9.5% of the company. Learn More about insider trades at Rigel Pharmaceuticals.
Information on this page was last updated on 2/4/2025.

Dean L. Schorno Insider Trading History at Rigel Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/4/2025	Sell	2,036	$20.92	$42,593.12	58,969
2/2/2023	Sell	538	$16.60	$8,930.80	19,651
5/22/2019	Buy	5,000	$21.30	$106,500.00	4,672

Dean L. Schorno Buying and Selling Activity at Rigel Pharmaceuticals

Rigel Pharmaceuticals Company Overview

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Today's Range

Now: $47.38

$46.76

$48.50

50 Day Range

MA: $35.50

$26.83

$50.96

2 Week Range

Now: $47.38

$14.63

$52.24

Volume

395,257 shs

Average Volume

650,314 shs

Market Capitalization

$859.95 million

P/E Ratio

7.68

Dividend Yield

N/A

Beta

1.11

Dean Schorno Biography and Net Worth

What is Dean L. Schorno's net worth?

How old is Dean L. Schorno?

What is Dean L. Schorno's salary?

How do I contact Dean L. Schorno?

Has Dean L. Schorno been buying or selling shares of Rigel Pharmaceuticals?

Who are Rigel Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Rigel Pharmaceuticals?